Sélectionner la langue
PSMA
PSMA Informations sur la molécule
| Nom anglais | Prostate-Specific Membrane Antigen | Nombre de médicaments commercialisés | 5 |
| Nombre de médicaments cliniques | 111 | Alias de la cible | EC:3.4.17.21，GIG27，Glutamate carboxypeptidase II，NAALADase I，FOLH，Cell growth-inhibiting gene 27 protein，PSM，N-acetylated-alpha-linked acidic dipeptidase I，GCPII，Folylpoly-gamma-glutamate carboxypeptidase，Folate hydrolase 1，FOLH1，Pteroylpoly-Gamma-Glutamate Carboxypeptidase，Membrane Glutamate Carboxypeptidase，Glutamate Carboxypeptidase 2，Glutamate Carboxylase II，NAALAD1，FGCP，PSMA，MGCP，Folate Hydrolase (Prostate-Specific Membrane Antigen) 1，N-Acetylated Alpha-Linked Acidic Dipeptidase 1，Prostate Specific Membrane Antigen Variant F，Prostate-Specific Membrane Antigen，EC 3.4.17.21，NAALAdase，GCP2 |
| Phase de R&D la plus avancée | Approved | ||
| Nom anglais | Prostate-Specific Membrane Antigen |
| Alias de la cible | EC:3.4.17.21，GIG27，Glutamate carboxypeptidase II，NAALADase I，FOLH，Cell growth-inhibiting gene 27 protein，PSM，N-acetylated-alpha-linked acidic dipeptidase I，GCPII，Folylpoly-gamma-glutamate carboxypeptidase，Folate hydrolase 1，FOLH1，Pteroylpoly-Gamma-Glutamate Carboxypeptidase，Membrane Glutamate Carboxypeptidase，Glutamate Carboxypeptidase 2，Glutamate Carboxylase II，NAALAD1，FGCP，PSMA，MGCP，Folate Hydrolase (Prostate-Specific Membrane Antigen) 1，N-Acetylated Alpha-Linked Acidic Dipeptidase 1，Prostate Specific Membrane Antigen Variant F，Prostate-Specific Membrane Antigen，EC 3.4.17.21，NAALAdase，GCP2 |
| Nombre de médicaments commercialisés | 5 |
| Nombre de médicaments cliniques | 111 |
| Phase de R&D la plus avancée | Approved |
PSMA Liste de produits
- Attribut
Protein (13)Beads (1)Antibody (1)Cell (1)Kits (1)
- Bibliothèque de produits
En ligne (17)
- Espèces
Human (9)Cynomolgus (2)Mouse (4)Rat (1)Rabbit (1)
- Étiquette
His Tag (6)His Tag & Avi Tag (3)Fc Tag (2)- (4)Fc Tag & Avi Tag (2)
- Marqueur
Unconjugated (7)Biotin-labeled (5)FITC Labeled (1)- (3)PE Labeled (1)
Ajouter au panier
Quantité totale17
- 1
- 2
PSMAContexte de la molécule
Prostate-specific membrane antigen (PSMA) is also known as Folate hydrolase 1 (FOLH1), Glutamate carboxypeptidase 2 (GCP2), N-acetylated-alpha-linked acidic dipeptidase I (NAALAD1), which belongs to the peptidase M28 family and M28B subfamily. FOLH1 / PSMA is stable at pH greater than 6.5. FOLH1 / PSMA is a type II transmembrane zinc metallopeptidase that is most highly expressed in the nervous system, prostate, kidney, and small intestine. FOLH1 / GCP-2 is homodimer and binds 2 zinc ions per subunit, and required for NAALADase activity. The catalytic activity of PSMA involved in releasing of an unsubstituted, C-terminal glutamyl residue, typically from Ac-Asp-Glu or folylpoly – gamma - glutamates. FOLH1 / GCP-2 / PSMA has both folate hydrolase and N – acetylated – alpha – linked - acidic dipeptidase (NAALADase) activity and has a preference for tri-alpha-glutamate peptides. GCP-2 / PSMA involved in prostate tumor progression and also exhibits a dipeptidyl-peptidase IV type activity. In vitro, cleaves Gly-Pro-AMC.
PSMAAlias de la molécule
FOLH1,PSMA,GIG27,FOLH,NAALAD1,PSM,NAALADase I,GCPII,FGCP
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| 225 Actinium PSMA-617 | 225Ac-PSMA 617; 225 Actinium PSMA-617; AAA 817; 225Ac-PSMA-617 | Phase 3 Clinical | Novartis Pharma Ag, Endocyte Inc, Advanced Accelerator Applications Sa | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
| 18F-PSMA-1007 | 18F-PSMA-1007 | Phase 3 Clinical | Deutsches Krebsforschungszentrum | Carcinoma, Renal Cell; Neoplasms; Prostatic Neoplasms | Details |
| Gallium-68 PSMA-617 | 225 Ac-PSMA-617; 68Ga-PSMA-617; 68Ga-DKFZ-617; 68Ga-DKFZ-PSMA -617; Gallium-68-PSMA-617; PSMA-617-[68Ga]; 68Ga-DOTA-PSMA-DKFZ -617 | Phase 3 Clinical | Peking Union Medical College Hospital | Carcinoma, Adenoid Cystic; Prostatic Neoplasms | Details |
| Vidoflufolastat (18F) | CTT-1057-F-18; CTT-1057-18F; 18F-CTT1057; CTT-1057 | Phase 3 Clinical | Washington University, Cancer Targeted Technology Llc | Carcinoma, Renal Cell; Prostatic Neoplasms | Details |
| Lutetium-177 zadavotide guraxetan | Phase 3 Clinical | Curium Us Llc | Prostatic Neoplasms | Details | |
| INR-101 | INR101; INR-101; INR101 PET CT; INR101-PET/CT | Phase 3 Clinical | Cloud Nuclear Medicine (Tianjin) Co Ltd | Prostatic Neoplasms; Diagnostic agents | Details |
| Nizaracianine triflutate | ZW800-1 | Phase 3 Clinical | Leiden University Medical Center, Curadel Surgical Innovations Inc | Ureteral Diseases | Details |
| ITM-24D | ITM-24D; 68Ga-PSMA-TTM | Phase 3 Clinical | ITM Isotope Technologies Munich SE | Prostatic Neoplasms | Details |
| 18F vipivotide tetraxetan | 18F-PSMA-617; Al18F-PSMA-617 | Phase 3 Clinical | Peking Union Medical College Hospital | Prostatic Neoplasms | Details |
| 64Cu-PSMA I&T | Copper Cu 64 PSMA I&T; Cu-64-PSMA-I&T; 64-Copper-PSMA-I&T; Copper-64-prostate specific membrane antigen I&T | Phase 3 Clinical | Curium Us Llc | Prostatic Neoplasms | Details |
| Thretide[18F] | 18F-LNC1001; 18F-LNC-1001 | Phase 3 Clinical | Neoplasms; Prostatic Neoplasms; Diagnostic agents | Details | |
| 64Cu-SAR-bisPSMA (Clarity Pharmaceuticals) | Phase 3 Clinical | Clarity Pharmaceuticals Ltd | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details | |
| 177Lu-DOTA-rosopatamb | 177Lu-DOTA-TLX591-CHO; TLX591 | Phase 3 Clinical | Telix Pharmaceuticals Ltd | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
| [Lu177]-PNT-2002 | PNT-2002 | Phase 3 Clinical | Point Biopharma Inc | Carcinoma, Renal Cell; Prostatic Neoplasms, Castration-Resistant; Carcinoma, Adenoid Cystic; Prostatic Neoplasms | Details |
| Lutetium-177-PSMA-I&T | Phase 2 Clinical | Radboud University Nijmegen | Salivary Gland Neoplasms; Carcinoma, Adenoid Cystic; Prostatic Neoplasms | Details | |
| 177Lu-PSMA-R2 | 177Lu-PSMA-R2; 177Lu-PSMA-SR6; AAA-602 | Phase 2 Clinical | Advanced Accelerator Applications Sa | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
| 89Zr-DFO-huJ591 | Zr89-J591; 89Zr-DFO-J591; 89Zr-DFO-huJ591 | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center | Prostatic Neoplasms | Details |
| Nezastomig | REGN-5678 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Carcinoma, Renal Cell; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
| 225Ac-J591 | 225Ac-DOTA-J591; 225Ac-J591; CONV 01-α; J591-Ac-225 | Phase 2 Clinical | Cornell University | Prostatic Neoplasms | Details |
| ATL-101 | MLN-591RL; ATL-101; huJ-591; MLN-591; J-591; Lu-177-J591; 177Lu-J591; 90Y-J591; muJ-591 | Phase 2 Clinical | Weill Medical College of Cornell University | Ovarian Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung | Details |
| [131I]MIP-1095 | 1095; [131I]MIP-1095; [131I]MIP-1466; 131I-MIP-1095; 131-I-MIP-1466; 131I-MIP-1466 | Phase 2 Clinical | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details | |
| CONV-01-alpha + PSMA I&T | Phase 2 Clinical | Convergent Therapeutics Inc | Prostatic Neoplasms | Details | |
| LAVA-1207 | LAVA-1207 | Phase 2 Clinical | Vu University Medical Center, Lava Therapeutics NV | Prostatic Neoplasms, Castration-Resistant | Details |
| 161Tb-NYM032 | 161Tb-NYM032 | Phase 2 Clinical | Prostatic Neoplasms, Castration-Resistant | Details | |
| RHN001-Dx (99mTc-PSMA) | technetium-99m (99mTc); Technetium 99m-RHN 001; 99mTc-RHN001 | Phase 2 Clinical | Heidelberg University Hospital, Telix Pharmaceuticals Ltd | Prostatic Neoplasms | Details |
| RHN001-Tx (188Re-PSMA) | RHN001-Tx (188Re-PSMA); rhenium-188- RHN 001; Rhenium-188 RHN 001 (188Re) | Phase 2 Clinical | Telix Pharmaceuticals Ltd, Heidelberg University Hospital | Prostatic Neoplasms | Details |
| In-111 rosopatamab tetraxetan | Phase 2 Clinical | Convergent Therapeutics Inc | Prostatic Neoplasms, Castration-Resistant | Details | |
| Ac-225 rosopatamab tetraxetan | Phase 2 Clinical | Convergent Therapeutics Inc | Prostatic Neoplasms, Castration-Resistant | Details | |
| 177Lu-LNC1011 | 177Lu-LNC1011; 177LuLNC1011 | Phase 2 Clinical | Yantai Lanna Cheng Biotechnology Co Ltd | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
| DGPR-1008 | DGPR1008; DGPR-1008 | Phase 2 Clinical | Xindou Biotechnology (Suzhou) Co Ltd | Contrast agents; Prostatic Neoplasms | Details |
| 68Ga-NYM032 | 68Ga-NYM032; 68GaNYM032 | Phase 2 Clinical | Wuxi Nuoyu Pharmaceutical Technology Co Ltd | Prostatic Neoplasms; Contrast agents | Details |
| 177Lu-NYM032 | 177Lu-NYM032; 177LuNYM032 | Phase 2 Clinical | Wuxi Nuoyu Pharmaceutical Technology Co Ltd | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
| AMX-500 | SAR-446329; SAR446329; VIR-5500; AMX-500 | Phase 2 Clinical | Amunix Pharmaceuticals Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| [225Ac]Ac-PSMA-R2 | AAA802; [225Ac]Ac-PSMA-R2; AAA-802 | Phase 2 Clinical | Novartis Pharma Ag | Prostatic Neoplasms | Details |
| 177Lu-PSMA | 177Lu-PSMA | Phase 2 Clinical | Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori | Carcinoma, Renal Cell; Neoplasms; Prostatic Neoplasms; Neoplasm Metastasis | Details |
| [177Lu]JH020002 | JH02; JH-02; JH-002; JH002; [177Lu]JH020002; 177-Lu JH-020002; Lu 177 JH020002 | Phase 2 Clinical | Bivision Biomedical Technology (Nanjing) Co Ltd | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
| HRS-4357 | Phase 2 Clinical | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details | ||
| [177Lu]Lu-XT033 | [177Lu]Lu-XT033 | Phase 2 Clinical | Beijing Xiantong International Technology Co Ltd | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
| Ga-68-NGUL | Phase 2 Clinical | Cellbion Co Ltd | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details | |
| CD19/70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
| GD2/PSMA Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR GD2/PSMA | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Solid tumours | Details |
| PSMA/CD70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR PSMA/CD70 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
| 177Lu-rhPSMA-10.1 | 177Lu-rhPSMA10.1; (177Lu) rhPSMA-10.1; Lutetium (177Lu) rhPSMA-10.1 (Tx IMP); Lutetium-177 rhPSMA10.1; Lutetium Lu 177 PSMA-10.1; 177Lu rhPSMA-10.1; Lu177-rhPSMA; 177Lu Radiohybrid PSMA-10.1; 177Lu-rhPSMA-10.1; 177Lu-rhPSMA | Phase 2 Clinical | Technical University Munich | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Urogenital Neoplasms; Prostatic Diseases | Details |
| Lu-177-DGUL | PSMA-D GUL; Lu-177-DGUL; 177Lu-DOTA-GUL | Phase 2 Clinical | Cellbion Co Ltd | Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
| 68Ga-PSMA-IRDye | TLX591-Sx | Phase 2 Clinical | Telix Pharmaceuticals Ltd | Prostatic Neoplasms | Details |
| REGN-4336 | REGN-4336 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| [177Lu]Ludotadipep | 177Lu-FC705; 177Lu-FC-705 | Phase 2 Clinical | Futurechem | Prostatic Neoplasms, Castration-Resistant | Details |
| 67Cu-SAR-bisPSMA (Clarity Pharmaceuticals) | Phase 2 Clinical | Clarity Pharmaceuticals Ltd | Prostatic Neoplasms, Castration-Resistant | Details | |
| IS-002 | IS-002 | Phase 2 Clinical | Intuitive Surgical Medical Device Science & Technology (Shanghai) Co Ltd | Prostatic Neoplasms | Details |
| Zopocianine | OTL-78; OTL78 | Phase 2 Clinical | Purdue University, Novartis Pharma Ag | Prostatic Neoplasms | Details |
| INO-5401 | INO-5401 | Phase 2 Clinical | Inovio Pharmaceuticals Inc | Glioblastoma; Carcinoma, Transitional Cell | Details |
| JNJ-63898081 | JNJ-8081; JNJ-63898081 | Phase 1 Clinical | Johnson & Johnson Innovative Medicine | Neoplasms | Details |
| P28z-CAR | P28z-CAR | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center, United States Department Of Defense | Prostatic Neoplasms | Details |
| PSMA-CART cell therapy (Shanghai Bioray Laboratory) | Phase 1 Clinical | BRL Medicine Inc | Prostatic Neoplasms, Castration-Resistant | Details | |
| Autologous T-cell therapy (anti-PSMA-CD3), Roger Williams Medical Center | Phase 1 Clinical | Roger Williams Medical Center | Prostatic Neoplasms | Details | |
| CC-1 | CC-1 | Phase 1 Clinical | Prostatic Neoplasms | Details | |
| Acapatamab | AMG-160 | Phase 1 Clinical | Amgen Inc | Prostatic Neoplasms, Castration-Resistant; Carcinoma, Non-Small-Cell Lung | Details |
| 177Lu-EB-vipivotide tetraxetan | 177-Lu-EB-PSMA-617 | Phase 1 Clinical | Peking Union Medical College Hospital, National Institute For Biomedical Imaging And Bioengineering (Nibib) | Carcinoma, Renal Cell; Prostatic Neoplasms, Castration-Resistant; Carcinoma, Adenoid Cystic; Prostatic Neoplasms | Details |
| [177Lu]-CTT-1403 | CTT-1403; [177Lu]CTT1403; 177Lutetium CTT1403; [177Lu]CTT-1403 | Phase 1 Clinical | Cancer Targeted Technology Llc | Prostatic Neoplasms | Details |
| Pelgifatamab corixetan | BAY-2315497 | Phase 1 Clinical | Bayer AG | Prostatic Neoplasms, Castration-Resistant | Details |
| PSMA CAR-T | Phase 1 Clinical | University Of Pennsylvania | Hormone-Resistant Prostate Neoplasms; Prostatic Neoplasms | Details | |
| [18F]F-DCFPyL | [18F]F-DCFPyL | Phase 1 Clinical | Anhui Provincial Hospital | Prostatic Neoplasms | Details |
| [18F]AlF-PSMA-N5 | [18F]AlF-PSMA-N5 | Phase 1 Clinical | Anhui Provincial Hospital | Prostatic Neoplasms | Details |
| AS-1986NS | Phase 1 Clinical | Antelope Surgical Solutions Inc | Prostatic Neoplasms | Details | |
| [177Lu]Lu-BQ7876 | Lutetium-177 Labeled BQ7876; [177Lu]Lu-BQ7876 | Phase 1 Clinical | Tomsk National Research Medical Center Of The Russian Academy Of Sciences | Prostatic Neoplasms | Details |
| 68Ga-AAZTA-NI-093 | Phase 1 Clinical | First Affiliated Hospital Of Fujian Medical University | Prostatic Neoplasms | Details | |
| [177Lu]Lu-PSMA-137 | [177Lu]Lu-PSMA-137 | Phase 1 Clinical | The First Affiliated Hospital Of Beijing University | Prostatic Neoplasms | Details |
| 68Ga-PSMA-0057 | Phase 1 Clinical | Suzhou Ruihe Pharmaceutical Technology Co Ltd | Prostatic Neoplasms | Details | |
| IR800-IAB2MA | IR800-IAB2MA | Phase 1 Clinical | Imaginab Inc | Kidney Neoplasms; Prostatic Neoplasms | Details |
| 177Lu-TR0471 | 177Lu-TR0471; 177LuTR0471 | Phase 1 Clinical | Tongrui Biopharmaceutical (Chengdu) Co Ltd | Prostatic Neoplasms, Castration-Resistant | Details |
| [18F]F-PSMA-N5 | [18F]F-PSMA-N5 | Phase 1 Clinical | Anhui Provincial Hospital | Prostatic Neoplasms | Details |
| PSW-1025 | PSW-1025 | Phase 1 Clinical | Osaka University, Japan Agency For Medical Research And Development | Prostatic Neoplasms | Details |
| 68Ga-AAZTA-093 | 68Ga-AAZTA-093 | Phase 1 Clinical | First Affiliated Hospital Of Fujian Medical University | Prostatic Neoplasms | Details |
| 99mTc-QULIC-5-P1 | 99mTc-QULIC-5-P1 | Phase 1 Clinical | First Affiliated Hospital Of Chongqing Medical University | Prostatic Neoplasms | Details |
| 68Ga-PSFA | 68Ga-PSFA | Phase 1 Clinical | First Affiliated Hospital Of Chongqing Medical University | Adenomatous Polyposis Coli | Details |
| 161Tb-SibuDAB | Phase 1 Clinical | University Hospital Basel | Prostatic Neoplasms, Castration-Resistant | Details | |
| Actinium-225 FL 020 (Full-Life Technologies) | 225-Ac FL-020; 225Ac-FL-020 | Phase 1 Clinical | Full Life Technologies Ltd | Prostatic Neoplasms, Castration-Resistant | Details |
| [Ac-225]-PSMA-62 | [Ac-225]-PSMA-62 | Phase 1 Clinical | Point Biopharma Inc | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Hormone-Sensitive Prostate Neoplasms | Details |
| 111In-PSMA-Trillium | BAY-3632687; BAY3632687 | Phase 1 Clinical | Bayer AG | Prostatic Neoplasms, Castration-Resistant; Prostatism | Details |
| JNJ-9401 | JNJ-9401 | Phase 1 Clinical | Xencor Inc | Prostatic Neoplasms | Details |
| ABBV-969 | ABBV-969; ABBV969 | Phase 1 Clinical | Abbvie Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| BAY-3563254 | BAY-3563254; BAY3563254 | Phase 1 Clinical | PSMA Therapeutics Inc, Noria Therapeutics Inc | Prostatic Neoplasms, Castration-Resistant; Prostatism; Prostatic Neoplasms | Details |
| JNJ-87189401 | JNJ-87189401 | Phase 1 Clinical | Janssen Research & Development Llc | Prostatic Neoplasms | Details |
| Actinium-225-macropa-pelgifatamab | BAY-3546828; BAY3546828 | Phase 1 Clinical | Bayer AG | Prostatic Neoplasms, Castration-Resistant | Details |
| 177Lu-PSMA-0057 | 177Lu-PSMA-0057 | Phase 1 Clinical | Nanjing First Hospital, Nanjing Medical University | Prostatic Neoplasms | Details |
| [68Ga]Ga-PSMA-D5 | [68Ga]Ga-PSMA-D5 | Phase 1 Clinical | Anhui Provincial Hospital | Prostatic Neoplasms | Details |
| 177Lu-LNC1003 | 177Lu-LNC1003 | Phase 1 Clinical | Yantai Lanna Cheng Biotechnology Co Ltd | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
| HRS-9815 | HRS-9815; HRS9815 | Phase 1 Clinical | Prostatic Neoplasms; Diagnostic agents | Details | |
| PSMA-Targeted [In-111]-Labeled Trillium Compound | Phase 1 Clinical | Ratio Therapeutics Inc | Prostatic Neoplasms | Details | |
| Autologous T cells therapy(Unicar-Therapy) | Phase 1 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Prostatic Neoplasms | Details | |
| 212Pb-NG001 | 212Pb-NG001; AB-001; AB001 | Phase 1 Clinical | ARTBIO Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| CART-PSMA cells（Nova Therapeutics） | Phase 1 Clinical | Nova Therapeutics LLC | Prostatic Neoplasms | Details | |
| 68Ga-NY108 | 68-Ga-labeled NY-108; 68-Ga-labeled NYM032; 68Ga-NYM032 | Phase 1 Clinical | Affiliated Hospital of Jiangnan University | Prostatic Neoplasms | Details |
| 177Lu-P17-088 | 177Lu-P17-088 | Phase 1 Clinical | Peking Union Medical College Hospital | Prostatic Neoplasms, Castration-Resistant | Details |
| 177Lu-P17-087 | 177Lu-P17-087 | Phase 1 Clinical | Peking Union Medical College Hospital | Prostatic Neoplasms, Castration-Resistant | Details |
| JANX-007 | JANX-007; PSMA-TRACTr | Phase 1 Clinical | Janux Therapeutics Inc | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
| JNJ-80038114 | JNJ-80038114 | Phase 1 Clinical | Janssen Research & Development Llc | Prostatic Neoplasms | Details |
| CART-PSMA-TGFbRDN (University of Pennsylvania) | Phase 1 Clinical | University Of Pennsylvania | Prostatic Neoplasms | Details | |
| DXC-008 | DAC-008; DXC-008 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Solid tumours; Prostatic Neoplasms; Sarcoma, Ewing | Details |
| TNB-585 | TNB-585; AMG-340 | Phase 1 Clinical | Teneobio Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| CB-307 | CB-307; CB307 | Phase 1 Clinical | Crescendo Bioscience Inc | Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| Copper 64-DOTA-TLX 592 | 64Cu-TLX-592; 64Cu-DOTA-TLX592 | Phase 1 Clinical | Telix International Pty Ltd | Prostatic Neoplasms | Details |
| ARX-517 | ARX-517; ARX517 | Phase 1 Clinical | Ambrx Inc | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
| AVC-102 | AVC-102 | Phase 1 Clinical | AvenCell Therapeutics Inc | Kidney Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| CBP-1018 | CBP-1018 | Phase 1 Clinical | Coherent Biopharma Suzhou Co Ltd | Solid tumours; Carcinoma, Renal Cell; Prostatic Neoplasms; Lung Neoplasms | Details |
| CCW-702 | CCW-702 | Phase 1 Clinical | The Scripps Research Institute Inc, Abbvie Inc | Prostatic Neoplasms | Details |
| Anti-PSMA CAR T-cell therapy (TNK Therapeutics) | Phase 1 Clinical | Sorrento Therapeutics Inc | Neoplasms | Details | |
| CART-PSMA-TGFβRDN cell therapy (Tmunity Therapeutics) | TmPSMA-02 | Phase 1 Clinical | Tmunity Therapeutics Inc, University Of Minnesota, University Of Pennsylvania | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
| 68Ga-PSMA-R2 (Advanced Accelerator Applications SA) | Clinical | Advanced Accelerator Applications Sa | Prostatic Neoplasms | Details | |
| Lu-177-labeled PSMA ligands (Zentralklinik Bad Berka/Johns Hopkins University School of Medicine) | Clinical | Zentralklinik Bad Berka | Prostatic Neoplasms | Details | |
| [At-211] PSMA-5 | [At-211] PSMA-5 | Clinical | Osaka University | Prostatic Neoplasms | Details |
Informations sur les médicaments commercialisés
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Capromab pendetide | lndium-CYT-356; Indium-111-CYT-356; CYT-356; 111In CYT-356 | Approved | Eusa Pharma | ProstaScint | United States | Prostatic Neoplasms | Cytogen Corp | 1996-10-28 | Prostatic Neoplasms | Details |
| Piflufolastat F 18 | Approved | Johns Hopkins University | Pylarify, Pylclari | United States | Prostatic Neoplasms | Progenics Pharmaceuticals Inc | 2021-05-26 | Carcinoma, Renal Cell; Pancreatic Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Genital Neoplasms, Female; Diagnostic agents; Metastatic breast cancer; Castration-Sensitive Prostate Neoplasms; Carcinoma, Hepatocellular; Neoplasm Metastasis | Details | |
| Ga-68 PSMA-11 | Ga-68-PSMA-11; Ga-68-PSMA; 68Ga-HBED-CC-PSMA11; AAA517; [68Ga]Ga-PSMA-11; AAA-517 | Approved | Radiomedix Inc | Gallium Ga 68 Psma-11, Illuccix, ILLUCCIX, Locametz | United States | Prostatic Neoplasms | University Of California, Los Angeles, Telix Pharmaceuticals Ltd | 2020-12-01 | Neoplasm Recurrence, Local; Solid tumours; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Diagnostic agents; Carcinoma, Hepatocellular; Neoplasm Metastasis | Details |
| Lutetium (177Lu) vipivotide tetraxetan | 177-Lu-PSMA-617; AAA-617; Lu-177- RLT; PSMA-617-[177Lu]; Lutetium-177-PSMA-617 | Approved | Radiomedix Inc | PLUVICTO | United States | Prostatic Neoplasms, Castration-Resistant | Novartis Pharmaceuticals Corp | 2022-03-23 | Liver Neoplasms; Carcinoma, Renal Cell; Carcinoma, Verrucous; Prostatic Neoplasms, Castration-Resistant; Carcinoma, Adenoid Cystic; Prostatic Neoplasms; Carcinoma, Squamous Cell; Neoplasm Metastasis; Carcinoma, Hepatocellular | Details |
| Flotufolastat F-18 | (18F)-rhPSMA-7.3; 18FrhPSMA-7.3; 18F-rhPSMA-7.3; F-18-rhPSMA-7.3; Fluorine-18 rhPSMA; rhPSMA-7.3 (18F) | Approved | Blue Earth Diagnostics Inc, Technical University Munich | POSLUMA | United States | Prostatic Neoplasms | Blue Earth Diagnostics Ltd | 2023-05-25 | Prostatic Neoplasms; Contrast agents | Details |
Avis sur les produits
T***n2023-06-29
1Mettre un likeI ordered this product on Monday and received it by Friday! The product came neatly packed in dry ice with secure packaging. The reagent gave me good standard curves as I titrate the concentration of PSMA for my assay. I will order again next time.- T***n2021-09-22 3Mettre un likeI highly recommend for this supplier company .I received this order on Sep . 03 /2021 with enough dry ice for - 80C. Thank you acrobiosystems.
- Informations sur la molécule
- Liste de produits
- Informations sur les médicaments commercialisés
- Avis sur les produits
- Informations sur les médicaments cliniques
Partager vers :
Message en ligne
[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: Switzerland Innovation Park Basel Area, Novartis Campus, Lichtstrasse 35, 4056 Basel
Email：order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved